KRAS and lung carcinoma: The discovery and development of additional therapeutic targets for lung cancer has dramatically accelerated since 2013, with the approval of therapies targeted towards EGFR mutations, ALK-, ROS-1-, RET-, NTRK-1/2/3-fusions, METex14, BRAF and KRAS mutations, as well as PD-1/PD-L1 and CTLA-4 [9,44,45,46], which have their own respective unique AE risks [47].